Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound.

Autores
Rizzitelli, S.; Giustetto, P.; Cutrin, Juan Carlos; Delli Castelli, D.; Boffa, C.; Ruzza, M.; Menchise, V.; Molinari, F.; Aime, S.; Terreno, E.
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The main goal of this study was to assess the theranostic performance of a nanomedicine able to generate MRI contrast as a response to the release from liposomes of the antitumor drug Doxorubicin triggered by the local ex- posure to pulsed low intensity non focused ultrasounds (pLINFU). In vitro experiments showed that Gadoteridol was an excellent imaging agent for probing the release of Doxorubicin following pLINFU stimulation. On this basis, the theranostic system was investigated in vivo on a syngeneic murine model of TS/A breast cancer. MRI offered an excellent guidance for monitoring the pLINFU-stimulated release of the drug. Moreover, it provided: i) an in vivo proof of the effective release of the liposomal content, and ii) a confirmation of the therapeutic ben- efits of the overall protocol. Ex vivo fluorescence microscopy indicated that the good therapeutic outcome was originated from a better diffusion of the drug in the tumor following the pLINFU stimulus. Very interestingly, the broad diffusion of the drug in the tumor stroma appeared to be mediated by the presence of the liposomes themselves. The results of this study highlighted either the great potential of US-based stimuli to safely trigger the release of a drug from its nanocarrier or the associated significant therapeutic improvement. Finally, MRI demonstrated to be a valuable technique to support chemotherapy and monitoring the outcome. Furthermore, in this specific case, the theranostic agent developed has a high clinical translatability because the MRI agent uti- lized is already approved for human use.
Fil: Rizzitelli, S.. Universita di Torino; Italia
Fil: Giustetto, P.. Universita di Torino; Italia
Fil: Cutrin, Juan Carlos. Universita di Torino; Italia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas (i); Argentina
Fil: Delli Castelli, D.. Universita di Torino; Italia
Fil: Boffa, C.. Universita di Torino; Italia
Fil: Ruzza, M.. Universita di Torino; Italia
Fil: Menchise, V.. Universita di Torino; Italia
Fil: Molinari, F.. Politecnico Di Torino; Italia
Fil: Aime, S.. Universita di Torino; Italia
Fil: Terreno, E.. Universita di Torino; Italia
Materia
Theranostic
Mri
Non Focused Ultrasound
Cancer
Doxorubicin
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/8379
Acceder
id CONICETDig_21cef1a173aec2b0fbb4f6b730c96f91
oai_identifier_str oai:ri.conicet.gov.ar:11336/8379
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound.Rizzitelli, S.Giustetto, P.Cutrin, Juan CarlosDelli Castelli, D.Boffa, C.Ruzza, M.Menchise, V.Molinari, F.Aime, S.Terreno, E.TheranosticMriNon Focused UltrasoundCancerDoxorubicinhttps://purl.org/becyt/ford/3.4https://purl.org/becyt/ford/3The main goal of this study was to assess the theranostic performance of a nanomedicine able to generate MRI contrast as a response to the release from liposomes of the antitumor drug Doxorubicin triggered by the local ex- posure to pulsed low intensity non focused ultrasounds (pLINFU). In vitro experiments showed that Gadoteridol was an excellent imaging agent for probing the release of Doxorubicin following pLINFU stimulation. On this basis, the theranostic system was investigated in vivo on a syngeneic murine model of TS/A breast cancer. MRI offered an excellent guidance for monitoring the pLINFU-stimulated release of the drug. Moreover, it provided: i) an in vivo proof of the effective release of the liposomal content, and ii) a confirmation of the therapeutic ben- efits of the overall protocol. Ex vivo fluorescence microscopy indicated that the good therapeutic outcome was originated from a better diffusion of the drug in the tumor following the pLINFU stimulus. Very interestingly, the broad diffusion of the drug in the tumor stroma appeared to be mediated by the presence of the liposomes themselves. The results of this study highlighted either the great potential of US-based stimuli to safely trigger the release of a drug from its nanocarrier or the associated significant therapeutic improvement. Finally, MRI demonstrated to be a valuable technique to support chemotherapy and monitoring the outcome. Furthermore, in this specific case, the theranostic agent developed has a high clinical translatability because the MRI agent uti- lized is already approved for human use.Fil: Rizzitelli, S.. Universita di Torino; ItaliaFil: Giustetto, P.. Universita di Torino; ItaliaFil: Cutrin, Juan Carlos. Universita di Torino; Italia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas (i); ArgentinaFil: Delli Castelli, D.. Universita di Torino; ItaliaFil: Boffa, C.. Universita di Torino; ItaliaFil: Ruzza, M.. Universita di Torino; ItaliaFil: Menchise, V.. Universita di Torino; ItaliaFil: Molinari, F.. Politecnico Di Torino; ItaliaFil: Aime, S.. Universita di Torino; ItaliaFil: Terreno, E.. Universita di Torino; ItaliaElsevier Science2015-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/8379Rizzitelli, S.; Giustetto, P.; Cutrin, Juan Carlos; Delli Castelli, D.; Boffa, C.; et al.; Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound.; Elsevier Science; Journal Of Controlled Release; 202; 1-2015; 21-300168-3659enginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.jconrel.2015.01.028info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:34:58Zoai:ri.conicet.gov.ar:11336/8379instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:34:58.469CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound.
title Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound.
spellingShingle Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound.
Rizzitelli, S.
Theranostic
Mri
Non Focused Ultrasound
Cancer
Doxorubicin
title_short Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound.
title_full Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound.
title_fullStr Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound.
title_full_unstemmed Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound.
title_sort Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound.
dc.creator.none.fl_str_mv Rizzitelli, S.
Giustetto, P.
Cutrin, Juan Carlos
Delli Castelli, D.
Boffa, C.
Ruzza, M.
Menchise, V.
Molinari, F.
Aime, S.
Terreno, E.
author Rizzitelli, S.
author_facet Rizzitelli, S.
Giustetto, P.
Cutrin, Juan Carlos
Delli Castelli, D.
Boffa, C.
Ruzza, M.
Menchise, V.
Molinari, F.
Aime, S.
Terreno, E.
author_role author
author2 Giustetto, P.
Cutrin, Juan Carlos
Delli Castelli, D.
Boffa, C.
Ruzza, M.
Menchise, V.
Molinari, F.
Aime, S.
Terreno, E.
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Theranostic
Mri
Non Focused Ultrasound
Cancer
Doxorubicin
topic Theranostic
Mri
Non Focused Ultrasound
Cancer
Doxorubicin
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.4
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The main goal of this study was to assess the theranostic performance of a nanomedicine able to generate MRI contrast as a response to the release from liposomes of the antitumor drug Doxorubicin triggered by the local ex- posure to pulsed low intensity non focused ultrasounds (pLINFU). In vitro experiments showed that Gadoteridol was an excellent imaging agent for probing the release of Doxorubicin following pLINFU stimulation. On this basis, the theranostic system was investigated in vivo on a syngeneic murine model of TS/A breast cancer. MRI offered an excellent guidance for monitoring the pLINFU-stimulated release of the drug. Moreover, it provided: i) an in vivo proof of the effective release of the liposomal content, and ii) a confirmation of the therapeutic ben- efits of the overall protocol. Ex vivo fluorescence microscopy indicated that the good therapeutic outcome was originated from a better diffusion of the drug in the tumor following the pLINFU stimulus. Very interestingly, the broad diffusion of the drug in the tumor stroma appeared to be mediated by the presence of the liposomes themselves. The results of this study highlighted either the great potential of US-based stimuli to safely trigger the release of a drug from its nanocarrier or the associated significant therapeutic improvement. Finally, MRI demonstrated to be a valuable technique to support chemotherapy and monitoring the outcome. Furthermore, in this specific case, the theranostic agent developed has a high clinical translatability because the MRI agent uti- lized is already approved for human use.
Fil: Rizzitelli, S.. Universita di Torino; Italia
Fil: Giustetto, P.. Universita di Torino; Italia
Fil: Cutrin, Juan Carlos. Universita di Torino; Italia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas (i); Argentina
Fil: Delli Castelli, D.. Universita di Torino; Italia
Fil: Boffa, C.. Universita di Torino; Italia
Fil: Ruzza, M.. Universita di Torino; Italia
Fil: Menchise, V.. Universita di Torino; Italia
Fil: Molinari, F.. Politecnico Di Torino; Italia
Fil: Aime, S.. Universita di Torino; Italia
Fil: Terreno, E.. Universita di Torino; Italia
description The main goal of this study was to assess the theranostic performance of a nanomedicine able to generate MRI contrast as a response to the release from liposomes of the antitumor drug Doxorubicin triggered by the local ex- posure to pulsed low intensity non focused ultrasounds (pLINFU). In vitro experiments showed that Gadoteridol was an excellent imaging agent for probing the release of Doxorubicin following pLINFU stimulation. On this basis, the theranostic system was investigated in vivo on a syngeneic murine model of TS/A breast cancer. MRI offered an excellent guidance for monitoring the pLINFU-stimulated release of the drug. Moreover, it provided: i) an in vivo proof of the effective release of the liposomal content, and ii) a confirmation of the therapeutic ben- efits of the overall protocol. Ex vivo fluorescence microscopy indicated that the good therapeutic outcome was originated from a better diffusion of the drug in the tumor following the pLINFU stimulus. Very interestingly, the broad diffusion of the drug in the tumor stroma appeared to be mediated by the presence of the liposomes themselves. The results of this study highlighted either the great potential of US-based stimuli to safely trigger the release of a drug from its nanocarrier or the associated significant therapeutic improvement. Finally, MRI demonstrated to be a valuable technique to support chemotherapy and monitoring the outcome. Furthermore, in this specific case, the theranostic agent developed has a high clinical translatability because the MRI agent uti- lized is already approved for human use.
publishDate 2015
dc.date.none.fl_str_mv 2015-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/8379
Rizzitelli, S.; Giustetto, P.; Cutrin, Juan Carlos; Delli Castelli, D.; Boffa, C.; et al.; Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound.; Elsevier Science; Journal Of Controlled Release; 202; 1-2015; 21-30
0168-3659
url http://hdl.handle.net/11336/8379
identifier_str_mv Rizzitelli, S.; Giustetto, P.; Cutrin, Juan Carlos; Delli Castelli, D.; Boffa, C.; et al.; Sonosensitive theranostic liposomes for preclinical in vivo MRI-guided visualization of doxorubicin release stimulated by pulsed low intensity non-focused ultrasound.; Elsevier Science; Journal Of Controlled Release; 202; 1-2015; 21-30
0168-3659
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jconrel.2015.01.028
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier Science
publisher.none.fl_str_mv Elsevier Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613086106877952
score 13.070432

Publicaciones similares